Evidence map›Paper›PMID 41925314›Full record

ArticleMolecular pharmaceutics2026

Injected Eye, Fellow Eye and Systemic Pharmacokinetic Modeling of Intravitreally Administered Bevacizumab.

Maria Franz, Ravi Kumar Jairam, Guangda Ma, Wolfgang Rist, Holger Fuchs, Lars Kuepfer, Nina Hanke, Anna-Kaisa Rimpelä

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria FranzTranslational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Ravi Kumar JairamInstitute for Systems Medicine with Focus on Organ Interaction, University Hospital RWTH Aachen, 52062 Aachen, Germany.
Guangda MaDepartment of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Wolfgang RistDepartment of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Holger FuchsDepartment of Eye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Lars KuepferInstitute for Systems Medicine with Focus on Organ Interaction, University Hospital RWTH Aachen, 52062 Aachen, Germany.
Nina HankeTranslational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.ORCID 0000-0001-6166-8838
Anna-Kaisa RimpeläDepartment of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.ORCID 0000-0003-4093-3465

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Simulation of retinal drug concentrations after intravitreal administration is still challenging, due to knowledge gaps in ocular physiology such as the molecule-dependent permeability of ocular segments and the mechanisms determining a drugs' diffusion through the vitreous. Current models consider the eye as an isolated organ, however, especially if we are striving for predictions that rely on only plasma data, it is crucial to understand the blood-ocular barrier to draw conclusions for drug exposure in the eye. The aim of this study was (1) to examine large molecule disposition within the rabbit injected eye as well as in the systemic circulation and the uninjected fellow eye using bevacizumab as a tool compound, (2) to show gaps in the current understanding of physiological processes governing drug distribution in the eye and (3) to identify model parameters relevant for eye-plasma drug exchange. We developed a semimechanistic ocular compartmental model to describe large molecule disposition in injected eye, plasma and fellow eye, following intravitreal bevacizumab administration in rabbit, based on literature data. Observations in the fellow eye add additional value to the developed model as they provide valuable new information about the blood-ocular barrier. Starting with a base model building on literature assumptions, we refined the structural model and parameter estimates (e.g., by adjusting the retinal volume) to better describe the observed data in the fellow eye. The simulated concentration-time profiles from our refined model adequately described observed concentrations in the injected eye, plasma and fellow eye. The retinal volume fraction accessible for bevacizumab was estimated at 41% and the retinal pigment epithelium permeability at 5.9 · 10

Indexed as

Angiogenesis InhibitorsBevacizumabEyeAnimalsBlood-Retinal BarrierIntravitreal InjectionsModels, BiologicalPermeabilityRabbitsRetinaVascular Endothelial Growth Factor AVitreous BodyAngiogenesis InhibitorsBevacizumabVascular Endothelial Growth Factor Afellow eyeintravitreal (ivt)mechanistic modelingpermeabilitypharmacokineticsretina

Identifiers

PMID41925314
PMCPMC13148302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.